Department of Advanced Medical Science, Asahikawa Medical University, Asahikawa 078-8510, Hokkaido, Japan.
Division of Biomedical Research, Kitasato University Medical Center, Kitasato University, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan.
Int J Mol Sci. 2023 Mar 1;24(5):4778. doi: 10.3390/ijms24054778.
The advancement in epigenetics research over the past several decades has led to the potential application of epigenome-editing technologies for the treatment of various diseases. In particular, epigenome editing is potentially useful in the treatment of genetic and other related diseases, including rare imprinted diseases, as it can regulate the expression of the epigenome of the target region, and thereby the causative gene, with minimal or no modification of the genomic DNA. Various efforts are underway to successfully apply epigenome editing in vivo, such as improving target specificity, enzymatic activity, and drug delivery for the development of reliable therapeutics. In this review, we introduce the latest findings, summarize the current limitations and future challenges in the practical application of epigenome editing for disease therapy, and introduce important factors to consider, such as chromatin plasticity, for a more effective epigenome editing-based therapy.
在过去几十年中,表观遗传学研究的进展使得表观基因组编辑技术有可能应用于各种疾病的治疗。特别是,表观基因组编辑在治疗遗传和其他相关疾病方面具有潜在的应用价值,包括罕见的印记疾病,因为它可以调节目标区域的表观基因组的表达,从而调节致病基因,而对基因组 DNA 的修饰最小或没有。目前正在进行各种努力,以成功地将表观基因组编辑应用于体内,例如提高目标特异性、酶活性和药物传递,以开发可靠的治疗方法。在这篇综述中,我们介绍了最新的发现,总结了目前在将表观基因组编辑应用于疾病治疗的实际应用中的局限性和未来挑战,并介绍了一些重要的考虑因素,如染色质可塑性,以实现更有效的基于表观基因组编辑的治疗。